Congress Program

Program subject to change.

Monday, 14 October 2019

08:00-17:30

Registration 

08:50-09:00

Welcome and Opening of the Congress
Thomas Wilckens,
Innventis Israel & Germany

09:00-10:30

Precision Medicine and Omics Diagnostics
Chairperson: Alain van Gool, Radboudumc, The Netherlands

09:00-09:25

Moving Forward with Biomarkers in Precision Medicine 
Alain van Gool, Radboudumc, The Netherlands

  • Increasing need for personalized biomarkers to drive precision medicine
  • Better progress through applying lessons learned in new innovations
  • What is next?

09:25-09:50

Rare Diseases: A Perspective on the Development of Risk During Pregnancy
Michael Liebman, IPQ Analytics, USA

  • Risk for Rare Diseases may result from epigenetic events during fetal development
  • Current studies on impact of lifestyle and environmental exposures during fetal development are primarily anecdotal, i.e. result from specific hypothesis-driven studies
  • An integrated approach to examine epidemiologic and molecular processes of individual system development will facilitate a novel research paradigm

09:50-10:15


Metabolomics: A Tool for Precision Medicine

Gabi Kastenmüller, IBIS, Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum Munich, Germany
  • Metabolomics provides readouts of individual metabolic health, capturing net effects of genetic and variable extrinsic factors such as life style
  • Personal metabolomic profiles are highly individual and very stable over time despite the dynamics of metabolism when adapting to short-term metabolic challenges such as eating
  • Longitudinal changes of the overall personal metabolome associate with worse health outcomes in population-based cohorts, suggesting metabolomics as a promising tool for monitoring health

10:15-10:30

Discussion

10:30-11:00

Networking, Coffee Break and visit the Exhibition 

11:00-12:30

Rare Disease and IMIDs
Chairperson: Catherine Brownstein, Boston Children's Hospital, USA

11:00-11:25

Embracing New Strategies to Determine the Genetic Basis of Mendelian Disorders
Catherine Brownstein, Boston Children's Hospital, USA

  • An interdisciplinary approach is necessary for gene discovery in Rare Immune-Mediated Inflammatory Diseases
  • Precompetitive data sharing is an effective method of turning N of 1 cases into cohorts
  • As WES becomes more common, strategies and infrastructure to maximize discoveries and diagnoses are paramount

11:25-11:50

Rare Autoinflammation & Autoimmune Diseases
Nikolaus Rieber, Munich Clinic Schwabing, Germany

  • Autoinflammatory diseases are a recently defined set of innate immune disorders characterized by recurrent episodes of systemic and organ-specific inflammation
  • The discovery of the inflammasome reaction and later of amplified interferon signatures were hallmarks for unraveling the pathophysiology of these diseases
  • The individual therapeutic approach can be challenging and relies on personalized medicine as shown by an exemplary patient presentation

11:50-12:15

MicroRNAs in Juvenile Idiopathic Arthritis: Can we Learn More About Pathophysiological Mechanisms?
Isabelle Duroux-Richard, INSERM, France

  • Because of their specificity and stability, as well as their detectable presence in many body fluids, microRNAs have been proposed as diagnostic and prognosis biomarkers for precision medicine in many diseases
  • MicroRNA quantification in whole blood, serum or synovial fluid can serve to diagnose immune-mediated inflammatory disorders diseases and to predict clinical response to therapy
  • It is not premature to think that clinicians could have kit-based assays for miRNA quantification in the near future to offer personal medicine to arthritic patients

12:15-12:30

Discussion 

12:30-13:30

Networking, Lunch Break and visit the Exhibition 

13:30-15:00

Precision Medicine in IMID
Chairperson: Thomas Hugle, CHUV, Switzerland

13:30-13:50

Precision Medicine in Rheumatic Diseases: The Example of Rheumatoid Arthritis
Roberta Gualtierotti, Università degli Studi di Milano, Italy

  • Although the prognosis of rheumatoid arthritis has dramatically changed over the last few decades, the rate of responses to current treatments is still sub-optimal
  • There is a need for new biomarkers to predict treatment responses and adverse events
  • The importance of education and the participation of all of the stakeholders involved should not be overlooked

13:50-14:10

A Parker Project: Immunopathological Characteristics in Patients with Psoriatic Arthritis
Marie Skougaard Nielsen, Frederiksberg and Bispebjerg Hospital, Denmark

  • Treatment of Psoriatic Arthritis is based on clinical decision making which is complicated by diverse disease manifestations
  • Better biomarkers for disease stratification are needed
  • Precision medicine in psoriatic arthritis necessitates the incorporation of clinical data, patient-reported outcome together with information about immunocellular mechanisms
14:10-14:30
Which Events Initiate Diseases? Why Some Diseases Go to the Skin, Others to Internal Organs? How do Environmental Factors Influence Diseases?
Gabriela Riemekasten
, University Klinik Schleswig-Holstein, Germany
  • Regulatory antibodies in heathy donors , cancer, Alzheimer, and autoimmune diseases
  • Contribution of specific regulatory antibodies against G protein-coupled receptors in disease pathogenesis
  • How can we transfer our understanding to novel therapeutic approaches?
14:30-14:50
The Digital Cycle has Begun: New Tools Towards Precision Medicine in Rheumatology
Thomas Hugle
, CHUV, Switzerland
  • Early disease detection using digital applications
  • Digital biomarker and treatments
  • Machine learning for disease prediction and treatment stewardship
  • How digital solutions will influence shared decision making

14:50-15:00

Discussion 

15:00-15:30

Networking, Coffee Break and visit the Exhibition

15:30-17:00

The Socioeconomic and Industry Impact of Precision Medicine
Chairperson: Richard Barker, New Medicine Partners, UK

15:30-15:55

The Physician-Payer Relationship in Outcome-Based Payment Models
Mark Jamilkowski & Chris Gay, Evry Health, USA

  • A new approach to physician - payer relationships is needed if outcomes based payment is to accepted and successful
  • New technology and analytics tools are part of the answer
  • Collaboration and transparency are required 

15:55-16:20

Precision Medicines: Implications for Clinical Trial Design, Speed of Approval, Physician Understanding, and Patient Consent
Jonathan Darrow, Harvard Medical School, USA

  • Precision medicines are approved more quickly than non-precision medicines
  • Precision medicines trials are less likely to be randomized, controlled, or blinded
  • Greater regulatory flexibility has implications for physician understanding and patient consent

16:20-16:45


Precision Medicine - A Basis for Partnership Between Health Systems and Industry
Richard Barker
, New Medicine Partners, UK
  • How PM tools are taking us beyond cancer to chronic disease
  • The impact on healthy longevity and system sustainability if we get it right
  • The basis for a new partnership between industry and the health and social system it serves
16:45-17:00 
Discussion

17:00-17:30

Summary and Outlook Discussion



Tuesday, 15 October 2019

08:30-16:40

Registration

09:00-10:30

Data Sciences in Multiomics
Chairperson: Yves Lussier, The University of Arizona, USA

09:00-09:25

Complex Immunotherapeutic Response and Computational Models in Single-Subject Studies
Yves Lussier, The University of Arizona, USA

09:25-09:50

Multi-Omics Characterization of Induced Thyrotoxicosis
Tim Kacprowski
, Technical University of Munich, Germany

09:50-10:15

Plasma Proteome Profiling to Assess Human Health and Disease
Philipp Geyer, Max Planck Institute of Biochemistry, Germany

10:15-10:30

Discussion 

10:30-11:00

Networking, Coffee Break and visit the Exhibition 

11:00-12:30

Drug and Biomarker Discovery for IMIDs
Chairperson: Harsukh Parmar, Non-Executive Director & Biotech Innovator, UK/USA

11:00-11:25


Novel Breakthrough Immunotherapy for Complex Diseases such as Autoimmunity and Immuno-oncology
Harsukh Parmar, Non-Executive Director & Biotech Innovator, UK/
USA
  • Traditional R & D in Pharma has largely been reductionist and associated with high failure rates
  • More holistic methodologies need to be developed to improve probability of success and outcomes in autoimmunity and immune-oncology
  • Recent insights and technological advances make this possible and these methods need to be implemented to improve outcomes for patients on an individual basis

11:25-11:50


Extracting and Using Knowledge about Biomarkers from Structured and Unstructured Data
Lutz Weber, OntoChem IT Solutions, Germany
  • A new data source serving to select and compare biomarkers for your clinical trials
  • A comprehensive source for biomarker analytics 
  • Selecting the right target population for your therapeutic approach

11:50-12:15

Best Practice – Personalised Medication for Everyone
Herna Muñoz-Galeano,
HMG Systems Engineering, Germany

12:15-12:30

Discussion

12:30-13:30

Networking, Lunch Break and visit the Exhibition

13:30-15:15
“Discovery is seeing what everybody else has seen, and thinking what nobody else has thought.” ― Albert Szent-Gyorgyi 
A Roadmap towards Precision Medicine

Chairperson, Thomas Wilckens, InnVentis, Israel & Germany

13:30-14:15

Keynote: Introduction to the Israeli AI Landscape and Overview of the National AI Strategy 
Amnon Hezkiya, National Committee for AI, Machine Learning & Data Science in Healthcare and Entrepreneur, Israel 

14:15-14:45

The Future of Medical AI - From Physical and Theoretical Limits to Hard Computational Barriers
Jan Baumbach
, Technical University of Munich, Germany

14:45-15:15

Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
Thomas Wilckens, InnVentis, Israel & Germany

15:15-15:45

Networking, Lunch Break and visit the Exhibition

15:45-16:30
Panel Discussion
AI and the Future of Biomedical Research and Development
Moderator:Thomas Wilckens, InnVentis Israel & Germany

Amnon Hezkiya, Richard Barker, Jan Baumbach, Harsukh Parmar, Lutz Weber

16:30-16:40

 Congress Closing Remarks